Climb Bio, Inc.
Status: Publicly traded
Direct answer
Climb Bio, Inc. is publicly traded on NASDAQ under the ticker CLYM.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The...
Can you invest in Climb Bio, Inc.?
Yes. Climb Bio, Inc. trades publicly on NASDAQ as CLYM.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Climb Bio, Inc.
Detailed equity research is provided by MarketSnap.